Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Hemispherix and Antigenics' Vaccine Adjuvants: Indispensable for Vaccines
- Finally, there is general agreement that preventive vaccines and therapeutic vaccines are indispensable, especially when we are living an evolution when viral strains that used to infect species other than humans have begun to infect humans. These strains have severe symptoms and are, indeed, life-threatening. More important is that the...
- External links 2009-06-12
- Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great Promise
- The news from Mayo Clinic about the success of Medarex’ MEDX and Bristol-Myers Squibb’s BMY monoclonal antibody Ipilimumabcombination treatment on inoperable prostate cancer patients cannot be overlooked. The news might represent a breakthrough in prostate cancer treatment as Ipilimumab has demonstrated efficacy on the category of prostate cancer patients who...
- External links 2009-06-23
- Expecting FDA Approval for Eurand's Zenpep
- Eurand Inc. EURX is waiting for the FDA to decide upon its proprietary pancreatic enzyme product Zenpep for exocrine pancreatic insufficiency. The condition is associated with various diseases, including chronic pancreatitis, cystic fibrosis, pancreatic cancer, partial or total gastrectomy, pancreatic resection and other causes. The various causes of exocrine pancreatic...
- External links 2009-06-24
- Spectrum: FDA News on Zevalin Equals an Approval
- Spectrum Pharmaceuticals SPPI received a Complete Response letter from the FDA regarding its supplemental biologics License Application sBLA for Zevalin® (ibritumo-mab tiuxetan) for first-line consolidation setting for non-Hodgkin’s Lymphoma (NHL) patients. The FDA’s letter requested that Spectrum submits data files from the FIT study to support and verify...
- External links 2009-07-06
- OSI: Tarceva Approved as Maintenance Treatment for Lung Cancer
- Finally OSI Pharmaceuticals OSIP has reported its expected results from the SATURN study, which confirm that immediate treatment with Tarceva after initial chemotherapy delays the progression of advanced lung cancer and helps patients live longer. Advanced lung cancer has yet to find a satisfactory treatment. It still frustrates oncologists and...
- External links 2009-07-14
- Who Sold Sequenom Last Week and Why?
- Sequenom’s SQNM recent stock decline looked as if a program was set for selling SQNM as soon as the financial results were announced. The point is that the firm’s financial results had nothing to do with SQNM's price move, neither during the rally that took the stock up from a...
- External links 2009-08-10
- Sequenom Reaches Important Milestone
- Hello future. It did not take us long to welcome the arrival of what many have expected from Sequenom SQNM and many have doubted. The expected has, indeed, begun to show, and the doubt that should disappear will stay as long as the skeptics of Wall street are ideologists...
- External links 2009-09-23
- Onyx Pharmaceuticals: Could Acquiring Proteolix Be the Deal of the Year?
- Onyx’s ONXX stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm’s cancer drug Nexavar on a variety...
- External links 2009-10-22
- Cytokinetics' Market Potential
- In the news: Cytokinetics CYTK has initiated phase I clinical trial to investigate the pharmacokinetic profile of CK-2017357. Cytokinetics has also initiated the second part, or "Part B", of a previously initiated, Phase I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a small...
- External links 2009-11-12
- << Previous
- page 1 of 1
- Next >>
